7 April 2022 – UCB Pharma (division of UCB Australia Pty Ltd) Bimekizumab Bimzelx has been given approval and added to the TGA register of Australian Prescription Medicine https://www.tga.gov.au/apm-summary/bimzelx
The recommended dose of Bimzelx for adult patients with plaque psoriasis is 320 mg (given as 2 subcutaneous injections of 160 mg each) at Week 0, 4, 8, 12, 16 and every 8 weeks thereafter. For some patients with a body weight equal to or greater than 120 kg, a dose adjustment of 320 mg every 4 weeks after Week 16 may be considered (see Section 5.1 Pharmacodynamic properties, clinical trials). For further information refer to the Product Information.
PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING OUTCOMES
MARCH 2022 PBAC MEETING
Bimzelx received a positive recommendation from PBAC to add as a General Schedule Authority
Required (Written) listing for the treatment of adults with severe plaque psoriasis.